[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Lin et al., 1992 - Google Patents

Annexin VI is required for budding of clathrin-coated pits

Lin et al., 1992

Document ID
4272530082805400074
Author
Lin H
Südhof T
Anderson R
Publication year
Publication venue
Cell

External Links

Snippet

Isolated plasma membranes attached to a solid substratum at 4OC have numerous clathrin- coated pits. These pits initially are flat but become deeply invaginated after warming to 37%. The pits remain tethered to the membrane in this rounded condition unless sup plied with …
Continue reading at www.cell.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension

Similar Documents

Publication Publication Date Title
Lin et al. Annexin VI is required for budding of clathrin-coated pits
Futaki et al. Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization
EP1044013B9 (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
Imamoto et al. In vivo evidence for involvement of a 58 kDa component of nuclear pore‐targeting complex in nuclear protein import.
De Vries et al. Fluorescently labeled phosphatidylinositol transfer protein isoforms (α and β), microinjected into fetal bovine heart endothelial cells, are targeted to distinct intracellular sites
Weissmann et al. Interaction of immunoglobulins with liposomes.
Maher et al. Anomalous interaction of the acetylcholine receptor protein with the nonionic detergent Triton X-114.
US9211345B2 (en) Glycopeptide and uses thereof
Agrawal et al. Structure and function of Humanc-reactive protein
CA2631582C (en) Enzymatic large-scale synthesis of mucin glycoconjugates, and immunogenic applications thereof
Haigler et al. Production and characterization of antibody blocking epidermal growth factor: receptor interactions
Banerjee et al. Evidence that glycoprotein 96 (B2), a stress protein, functions as a Th2-specific costimulatory molecule
AU2354700A (en) Muc-1 antagonists and methods of treating immune disorders
KR100943197B1 (en) Oligopeptides for promoting hair growth
Snoek et al. The phosphatidylinositol transfer protein in 3T3 mouse fibroblast cells is associated with the Golgi system
Homma et al. Vitamin D‐binding protein (group‐specific component) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine
Kissmehl et al. Subplasmalemmal camstores in Paramecium tetraurelia. Identification and characterisation of a sarco (endo) plasmic reticulum-like Ca2+-ATPase by phosphoenzyme intermediate formation and its inhibition by caffeine
Ball et al. Mutational analysis of the rotavirus NSP4 enterotoxic domain that binds to caveolin-1
EP1315517B1 (en) Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
JP2005506276A (en) Antiallergic complex molecule
Janssen‐Timmen et al. Immunocytochemical localization of the gap junction 26 K protein in mouse liver plasma membranes.
CA2131623A1 (en) Prevention of suppression of immune defence against cancer caused by the cancer-associated scm-recognition peptides
Oddie et al. Modulation of pp60c‐src tyrosine kinase activity during secretion in stimulated bovine adrenal chromaffin cells
AU764581B2 (en) Novel anti-allergic agents
Taylor et al. GPI-anchored proteins in health and disease